AUR-AFE4-TTM6-A-1-1-R-A742-41
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.440
- PROTEIN_SECRETION+0.410
- FATTY_ACID_METABOLISM+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.360
- BILE_ACID_METABOLISM+0.330
- ESTROGEN_RESPONSE_EARLY+0.330
- XENOBIOTIC_METABOLISM+0.330
- ADIPOGENESIS+0.280
- MYC_TARGETS_V1+0.270
- DNA_REPAIR+0.250
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.590
- INFLAMMATORY_RESPONSE-0.500
- TNFA_SIGNALING_VIA_NFKB-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- HEDGEHOG_SIGNALING-0.460
- INTERFERON_GAMMA_RESPONSE-0.450
- KRAS_SIGNALING_UP-0.440
- IL6_JAK_STAT3_SIGNALING-0.430
- IL2_STAT5_SIGNALING-0.380
- INTERFERON_ALPHA_RESPONSE-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A06Z-01A-11R-A00Z-07 | — | B | 0.872 |
| 2 | TCGA-BH-A0H9-01A-11R-A056-07 | — | B | 0.855 |
| 3 | DRR168570 | — | — | 0.854 |
| 4 | SRR6013568 | — | cohortA2 | 0.854 |
| 5 | DRR168601 | — | — | 0.850 |
| 6 | 20120126.LumB | — | B | 0.849 |
| 7 | ULC1533T_S61 | — | cohortA2 | 0.847 |
| 8 | ULC0410T_S45 | — | cohortA4 | 0.846 |
| 9 | AUR-AG12-TTM1-A-1-1-R-A743-41 | — | C | 0.845 |
| 10 | SRR1313100 | — | B | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.360 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.360 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.330 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.330 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.280 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.070 | Binimetinib | — uncovered |